



Grand Council 2026

July 30th – August 1st

Title: Introduction to Tensynovial Giant Cell Tumors (TGCT)

Date and Time of CE Activity: Friday, July 31st, 2026, at 2:15 – 3:15 pm

Location: The Galt House Hotel in Louisville, Kentucky

Overview: Tenosynovial Giant Cell Tumor (TGCT) is a rare, locally aggressive joint neoplasm that causes chronic pain, joint destruction, and high surgical recurrence rates. The introduction of oral colony-stimulating factor 1 receptor (CSF1R) inhibitors has shifted management toward systemic targeted therapies; however, these medications carry significant black box warnings for severe hepatotoxicity and unique toxicity profiles. Pharmacists are uniquely positioned to help patients navigate these complexities, maximize therapy adherence, and improve quality of life. However, they frequently lack the specialized knowledge required to recognize this rare tumor type, interpret mandatory Risk Evaluation and Mitigation Strategies (REMS) criteria, manage medication adverse events, and advise patients on additional strategies to manage physical symptoms. Furthermore, pharmacists need education to effectively update healthcare providers on evolving treatment protocols and connect both providers and patients with available support resources.

Overall Activity Goal: The goal of this knowledge-based activity is to learn how to diagnose and treat TGCT tumors.

Target Audience – This activity is primarily intended for pharmacists from all practice settings. No prerequisites required.

Learning Objectives:

Upon completion of these activities, the participant should be able to:

Introduction to Tensynovial Giant Cell Tumors (TGCT)

UAN: 0064-9999-26-063-L/H01-P (0.1 CEU)

Pharmacist Objectives:

1. Describe differences and similarities between localized and diffuse TGCT.
2. List current treatment options for TGCT.
3. Identify barriers to care of patients.
4. Analyze strategies to educate providers and connect patients with available supportive care resources.
5. Review REMs requirements for applicable treatment.



Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for up to 1.0 hours of CPE credit (0.10 CEU). Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity; and 4) completing all self-assessment instruments and CE credit submission form. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Knowledge

Registration Fees: (Various registration fees apply) \$99 - \$400

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Planning Committee and Participating Faculty reported the following:

Participating Faculty: Julie Carter, PharmD, BCGP

Financial disclosures: No disclosures reported.

How to earn credit: Participants must complete the activity as described above in the Credit Designation Statement. In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Computer requirements: The broadcast will occur from a zoom webinar. Participants will need computer/tablet/or handheld device that includes an internet connection, speakers, microphone, and webcam. Supported browsers include Windows: Edge 12+, Firefox 27+, Chrome 30+ macOS: Safari 7+, Firefox 27+, Chrome 30+ or Linux: Firefox 27+, Chrome 30+. Processor and RAM requirements include Processor and RAM requirements: single core 1Ghz or higher and recommended RAM 4 Gb. Bandwidth requirements: For high-quality video: 1.0 Mbps/600kbps (up/down).

Grievance Policy – A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or co-provided by The University of Tennessee College of Pharmacy may contact the Director of Continuing Professional Development at jwheele4@uthsc.edu. The grievance will be reviewed, and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

Activity – The following is an educational activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of an introduction, activity, and self-assessment via cases.